In connection with the Company’s prior financing round in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

OU Online’s MS in Sustainability prepares students for career changes, advancement, and leadership in a growing sector impacting industries and organizations around the world. f. Students are welcome ...

Abstract: In this brief, for time-varying nonlinear systems, a novel approximate dynamic programming structure is first proposed to obtain the approximate optimal solution of the control system. In ...

The words that make up your compliance program documents are critical, there’s no doubt about that. But they will only ever be words on a page if their structure and design are disconnected. Mark ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.